Medial Patellofemoral Ligament Reconstruction Using Pedicled Quadriceps Tendon Autograft Yields Similar Clinical and Patient-Reported Outcomes but Less Donor-Site Morbidity Compared With Gracilis Tendon Autograft

Purpose: To compare clinical and patient -reported outcome measures (PROMs) in patients with recurrent patellar dislocation after medial patellofemoral ligament (MPFL) reconstruction using either a gracilis tendon (GT) or quadriceps tendon autograft (QT). Methods: All MPFL reconstruction performed between 2017 and 2019 were reviewed retrospectively. Only patients with isolated MPFL reconstruction, without any major patellofemoral risk factors and a minimum follow-up of 24 months, were included in the study. Patients were matched with respect to sex, age, and body mass index. All patients were evaluated clinically and using PROMs. Results: A total of 64 patients with an average follow up of 28.7 +/- 7.5 months were included in this study. The mean Kujala score (GT: 84.8 +/- 12.9, QT: 88.9 +/- 10.1), Lysholm score (GT: 89.4 +/- 10.2, QT: 88.4 +/- 5.0), and visual analog scale score for pain (GT: 1.9 +/- 1.8, QT: 1.1 +/- 1.3) did not significantly differ between both groups. Tegner activity level was significantly greater (P = .027) in the QT group (5.5 +/- 1.9) compared with the GT group (4.6 +/- 1.8), but within the minimal clinically important differences. Occasional patellar instability events, but no recurrent dislocation, were reported in 12.5% in the GT group and 6.3% in the QT group (P = .39). Of all patients, 90.6% in the QT and 68.8% in the HT group exceeded the PASS for the Kujala score (P = .06). Significantly more patients (59.4%) treated with GT reported donor -site morbidity in the form of sensitivity deficit at the lower leg compared with those treated with QT (3.1%, P = .001). Conclusions: GT and QT MPFL reconstruction have comparable PROMs and patellar redislocation rates 2 years' postoperatively. Significantly more patients treated with GT reported lower -leg sensitivity deficit compared with those treated with QT. Level of Evidence: Level III, retrospective caseecontrol study.